LONDON – The UK biotech industry published its wish list for 2015 – 2020, calling for further improvements to the tax regime, a continued focus on strategic technologies such as regenerative medicine and synthetic biology, and new, flexible routes for licensing, evaluation, reimbursement and market access of biologic drugs.
The manifesto, launched at the Bioindustry Association's (BIA) UK Bioscience Forum, represents the views of 1,000 companies that are lobbying for intensified support for the sector when the next government is elected in May 2015.
While acknowledging the backing that the current government and its predecessor have provided, the manifesto stated that this must be sustained and improved.
Biotechnology is "underpinned by the biggest change of the age" in the shape of the genomics revolution. "That's why it can attract talent and capital," Steve Bates, chief executive of the BIA told delegates. The sector deserves support, and